<DOC>
	<DOCNO>NCT02568462</DOCNO>
	<brief_summary>The purpose study evaluate safety performance new version coronary artery stent treat blockage artery supply blood heart muscle . The Amaranth Medical APTITUDE scaffold release drug ( sirolimus ) reduce likelihood treat blood vessel develop new blockage . In addition , scaffold dissolve away time , leave permanent implant blood vessel heal .</brief_summary>
	<brief_title>Safety Efficacy Study Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent</brief_title>
	<detailed_description>The objective study evaluate safety performance AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold use treatment single , de novo , stenotic native coronary artery lesion patient undergo elective percutaneous coronary intervention . The scaffold single-use device comprise balloon-expandable , intracoronary drug coat scaffold pre-mounted rapid-exchange delivery catheter . The scaffold make Poly-L-Lactide ( PLLA ) coat polymer-antiproliferative drug ( sirolimus ) matrix . The scaffold provide mechanical support similar metallic stent vessel healing , gradually breaks time leave permanent implant treat vessel . Compared prior version scaffold , new device thinner strut design ( wall thickness 120 µm rather 150 µm ) , otherwise identical . The study design prospective , non-randomized , multi-center , non-inferiority trial . It enroll maximum 60 patient 12 investigational center Colombia European Union . Eligible patient least 18 year age diagnose symptomatic ischemic disease due discrete , single , de novo , stenotic lesion native coronary artery ask participate study . After treatment investigational device , subject follow five year . Safety device evaluate use incidence target vessel failure follow-up period . Performance ( efficacy ) assess use in-scaffold late lumen loss measure quantitative coronary angiography nine month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>General 1 . Subject ≥ 18 year age &lt; 85 year age . 2 . Subject agree participate investigational device drug study period two year follow index procedure . Questionnairebased study , study noninvasive require investigational device medication allow . 3 . Subject ( legally authorize representative ) provide write informed consent prior studyrelated procedure , use form approve local Ethics Committee . 4 . Subject : 1. evidence myocardial ischemia ( e.g. , stable angina [ Canadian Cardiovascular Society 1 , 2 , 3 , 4 ] unstable angina [ Braunwald Class 13 , BC ] , silent ischemia support image study [ ETT , SPECT , stress echocardiography , Cardiac CT ] ) , 2. low intermediate risk NSTEMI , 3. evidence myocardial ischemia coronary territory previously affect STEMI long lesion fulfills angiographic inclusion criterion intervention perform ≥ 3 month follow STEMI . 5 . Subject acceptable candidate coronary artery bypass graft ( CABG ) surgery . 6 . Patient agree complete protocol require followup visit , include angiogram . 7 . Elective percutaneous intervention nontarget lesion allow perform ≥ 30 day prior follow index procedure . Angiographic 1 . Patient indicate elective stenting single , de novo , stenotic lesion native coronary artery . 2 . Target lesion must measure ≤ 14 mm length online QCA . 3 . Lesion must locate native coronary artery diameter ( average distal proximal lesion IVUS ) 2.5 mm 3.7 mm . 4 . Target lesion must major artery branch visually estimate diameter stenosis ≥ 50 % &lt; 100 % Thrombolysis Myocardial Infarction ( TIMI ) flow ≥ 1 . General 1 . Patient known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel , prasugrel , ticagrelor ) , sirolimus derivative , poly ( Llactide ) , poly ( D , Llactide ) , platinumiridium , contrast sensitivity adequately premedicated . 2 . Patient evolve ST segment elevation myocardial infarction ( STEMI ) . 3 . Patient current unstable arrhythmia . 4 . Patient leave ventricular ejection fraction ( LVEF ) &lt; 30 % . 5 . Patient receive heart transplant organ transplant , wait list organ transplant . 6 . Patient previous stent placement ≤ 15 mm ( proximal distal ) target lesion . 7 . Patient receive schedule receive chemotherapy malignancy ≤ 30 day prior index procedure . 8 . Patient receive immunosuppressant therapy and/or know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus , rheumatoid arthritis , severe asthma require immunosuppressive medication , etc. ) . 9 . Patient receive schedule receive chronic anticoagulation therapy ( e.g. , heparin , Coumadin ) stop restart accord local hospital standard procedure . 10 . Elective surgery plan ≤ 9 month index procedure require discontinuation antiplatelet medication . 11 . Patient platelet count &lt; 100,000 cells/mm^3 &gt; 700,000 cells/mm^3 , WBC &lt; 3,000 cells/mm^3 , document suspect liver disease ( include laboratory evidence hepatitis ) . 12 . Patient known renal insufficiency ( e.g. , eGFR &lt; 60 ml/kg/m^2 serum creatinine level &gt; 2.5 mg/dL , subject dialysis ) . 13 . Patient history bleed diathesis coagulopathy refuse blood transfusion . 14 . Patient cerebrovascular accident ( CVA ) transient ischemic neurological attack ( TIA ) ≤ 6 month prior index procedure . 15 . Patient significant GI urinary bleed ≤ 6 month prior index procedure . 16 . Patient extensive peripheral vessel disease preclude safe introducer sheath insertion . 17 . Patient receive brachytherapy epicardial vessel ( include side branch ) . 18 . Pregnant nursing subject plan pregnancy ≤ 2 year follow index procedure . ( Note : Female subject childbearing potential must negative pregnancy test ≤ 28 day prior index procedure agree use contraception 2 year . ) 19 . Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin , etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy ( i.e. , ≤ 1 year ) . 20 . Subject belongs vulnerable population ( per investigator 's judgment , e.g. , subordinate hospital staff , mentally deficient , unable read write ) . Angiographic Exclusion 1 . Target lesion meet follow criterion : 1 . Aortoostial location ( within ≤ 3 mm aorta junction ) . 2 . Left Main location . 3 . Located ≤ 3 mm origin leave anterior descending ( LAD ) leave coronary circumflex ( LCX ) . 4 . Located within arterial saphenous vein graft distal diseased ( defined vessel irregularity per angiogram &gt; 20 % stenosed lesion , visual estimation ) arterial saphenous vein graft . 5 . Lesion involve bifurcation &gt; 2 mm diameter ostial lesion &gt; 40 % stenosed visual estimation side branch require predilatation . 6 . Total occlusion ( TIMI flow 0 ) prior wire crossing . 7 . Excessive tortuosity ( ≥ two 45° angle ) , extreme angulation ( ≥ 90° ) proximal within target lesion . 8 . Restenotic previous intervention . 9 . Moderate severe superficial calcification ( defined calcium arch &gt; 120° ) proximal within target lesion . 2 . Target lesion involve myocardial bridge . 3 . Target vessel contains visible thrombus indicated angiographic image . 4 . Another clinically significant lesion locate major epicardial vessel target lesion ( include side branch ) . 5 . Inadequate predilation target lesion ( residual stenosis &gt; 40 % visual assessment ) . 6 . Patient high probability use ancillary device atherectomy cut balloon required time index procedure treatment target vessel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary Vessels</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Angina Pectoris</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Revascularization</keyword>
</DOC>